RxDoctor Payments Data

Jody Reiser, MD

Neurology · Phoenix, AZNPI 1194949560

Payments from drug & device makers

$2,114in general payments, 2019–2025

Across 148 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$930
  • AbbVie$267
  • Amneal Pharmaceuticals LLC$255
  • UCB, Inc.$151
  • Genentech USA, Inc.$149
  • Argenx US, Inc.$139
  • plus $223 from 4 others

What the payments were for

  • Speaking & faculty fees$975%
  • Food & beverage$2,00195%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,114 in reported general payments places this provider in the 45th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$69,492
Medicare patients
164
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate27$146,194
RytaryCarbidopa/Levodopa77$102,923
NourianzIstradefylline19$54,281
NeuproRotigotine33$36,995
BriviactBrivaracetam19$34,492
Emgality PenGalcanezumab-Gnlm29$21,324
AptiomEslicarbazepine Acetate11$18,867
CrexontCarbidopa/Levodopa15$10,238
Aimovig AutoinjectorErenumab-Aooe12$8,620
OxycontinOxycodone Hcl13$8,003
Levetiracetam108$4,601
Gabapentin121$2,863
Lamotrigine86$2,490
Carbidopa-LevodopaCarbidopa/Levodopa85$2,476
Duloxetine Hcl119$2,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$930$146,19427 claims
Amneal Pharmaceuticals LLCRytary, Crexont$255$113,16092 claims
UCB, Inc.Neupro, Briviact$151$71,48652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 388 neurology providers in Arizona.

Other neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →